- Home
- SKYE vs UONE Comparison
SKYE vs UONE Comparison
Compare SKYE & UONE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKYE
- UONE
- Stock Information
- Founded
- SKYE 2012
- UONE 1980
- Country
- SKYE United States
- UONE United States
- Employees
- SKYE N/A
- UONE N/A
- Industry
- SKYE Biotechnology: Pharmaceutical Preparations
- UONE Broadcasting
- Sector
- SKYE Health Care
- UONE Consumer Discretionary
- Exchange
- SKYE Nasdaq
- UONE Nasdaq
- Market Cap
- SKYE 73.4M
- UONE 68.9M
- IPO Year
- SKYE N/A
- UONE N/A
- Fundamental
- Price
- SKYE $2.16
- UONE $1.46
- Analyst Decision
- SKYE Buy
- UONE
- Analyst Count
- SKYE 6
- UONE 0
- Target Price
- SKYE $16.60
- UONE N/A
- AVG Volume (30 Days)
- SKYE 229.4K
- UONE 36.7K
- Earning Date
- SKYE 08-08-2025
- UONE 08-07-2025
- Dividend Yield
- SKYE N/A
- UONE N/A
- EPS Growth
- SKYE N/A
- UONE N/A
- EPS
- SKYE N/A
- UONE N/A
- Revenue
- SKYE N/A
- UONE $437,499,000.00
- Revenue This Year
- SKYE N/A
- UONE N/A
- Revenue Next Year
- SKYE N/A
- UONE N/A
- P/E Ratio
- SKYE N/A
- UONE N/A
- Revenue Growth
- SKYE N/A
- UONE N/A
- 52 Week Low
- SKYE $1.14
- UONE $1.23
- 52 Week High
- SKYE $9.73
- UONE $2.37
- Technical
- Relative Strength Index (RSI)
- SKYE 51.61
- UONE 41.69
- Support Level
- SKYE $2.12
- UONE $1.50
- Resistance Level
- SKYE $2.22
- UONE $1.78
- Average True Range (ATR)
- SKYE 0.19
- UONE 0.12
- MACD
- SKYE -0.02
- UONE -0.03
- Stochastic Oscillator
- SKYE 34.69
- UONE 20.59
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis, and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.
About UONE Urban One Inc.
Urban One Inc is an urban oriented, multi-media company. Its business is radio broadcasting franchise that is the radio broadcasting operation that targets African-American and urban listeners. It operates through the following segments: Radio Broadcasting, Reach Media, Digital, and Cable Television. The Radio Broadcasting segment includes all the broadcasting related operations. The Reach Media segment consists of the Tom Joyner Morning Show and its related activities. The Digital segment focuses on its online business, including the operations of Interactive One. The Cable Television segment deals with TV One's operations.